ALNY In Motion, Shire Finds New Use For Old Drug, TFX Snaps Up VASC

Alnylam Pharmaceuticals Inc. (ALNY), on Sunday, reported positive interim clinical results of its investigational RNAi therapeutic Fitusiran from an ongoing phase II open label extension study in patients with Hemophilia A or B without inhibitors.

from RTT - Biotech http://ift.tt/2gXeiC1
via IFTTT